Back to top
more

Health Catalyst (HCAT)

(Delayed Data from NSDQ)

$6.65 USD

6.65
956,177

-0.13 (-1.92%)

Updated May 8, 2024 04:00 PM ET

After-Market: $6.64 -0.01 (-0.15%) 6:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (99 out of 251)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Health Catalyst (HCAT) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Health Catalyst (HCAT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Insulet (PODD) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Insulet (PODD) is expected to have benefited from the ongoing rollout of Omnipod 5 in several international markets in the fourth quarter.

Ecolab (ECL) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Ecolab's (ECL) fourth-quarter results are likely to be driven by its Food & Beverage, Water business along with the Institutional segment.

DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the fourth quarter.

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Catalent's (CTLT) fiscal second-quarter results are likely to be driven by its non-COVID non-Sarepta Biologics business.

Bio-Rad Laboratories (BIO) to Post Q4 Earnings: What Awaits?

by Zacks Equity Research

Ongoing weakness in the biopharma end markets, impacting the sales of Life Science tools and bioprocessing products, are likely to have impeded Bio-Rad's (BIO) Q4 revenues.

Charles River (CRL) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

The service business within Charles River (CRL) RMS is expected to have witnessed growth in the fourth quarter, banking on small molecule revenue increase across several geographic regions.

Wall Street Analysts Believe Health Catalyst (HCAT) Could Rally 28.97%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 29% upside potential for Health Catalyst (HCAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Compared to Estimates, Health Catalyst (HCAT) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

All You Need to Know About Health Catalyst (HCAT) Rating Upgrade to Strong Buy

by Zacks Equity Research

Health Catalyst (HCAT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Health Catalyst (HCAT) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Health Catalyst (HCAT) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Health Catalyst (HCAT) delivered earnings and revenue surprises of 266.67% and 0.75%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Enovis (ENOV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Enovis (ENOV) delivered earnings and revenue surprises of 15.09% and 2.23%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Compared to Estimates, Health Catalyst (HCAT) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Health Catalyst (HCAT) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Health Catalyst (HCAT) Tops Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Health Catalyst (HCAT) delivered earnings and revenue surprises of 225% and 3.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axonics (AXNX) delivered earnings and revenue surprises of 44.12% and 9.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Does Health Catalyst (HCAT) Have the Potential to Rally 30.43% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 30.4% upside potential for Health Catalyst (HCAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Industry Outlook Highlights Inspire Medical Systems, Olink Holding and Health Catalyst

by Zacks Equity Research

Inspire Medical Systems, Olink Holding and Health Catalyst have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Info Systems Stocks Countering Industry-wide Headwinds

by Urmimala Biswas

Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Olink Holding (OLK) and Health Catalyst (HCAT) are expected to gain even as COVID-19 severity fades.

NextGen (NXGN) Riding on the Success of Cloud-Based Solution

by Zacks Equity Research

NextGen's (NXGN) cloud-based healthcare technology solutions boost the company's prospect. Strong adoption of its services continues to boost revenues.

Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Health Catalyst (HCAT) delivered earnings and revenue surprises of 50% and 1.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Olink Holding AB (publ) Sponsored ADR (OLK) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Olink Holding AB (publ) Sponsored ADR (OLK) delivered earnings and revenue surprises of 25% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

3 Medical Info Systems Stocks Braving Industry-wide Headwinds

by Urmimala Biswas

Zacks Medical Info Systems industry stocks like 10x Genomics (TXG), NextGen Healthcare (NXGN) and Health Catalyst (HCAT) are expected to gain as COVID-19 severity fades.

Does Health Catalyst (HCAT) Have the Potential to Rally 61% as Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 61.5% upside potential for Health Catalyst (HCAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Health Catalyst (HCAT) Climb 113% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 113% in Health Catalyst (HCAT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.